NCT06454175View on ClinicalTrials.gov

A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

August 3, 2024

Primary Completion Date

February 5, 2025

Study Completion Date

July 5, 2025

Conditions
HPV InfectionHPV-Related CarcinomaGenital WartHPV-Related Intraepithelial Neoplasia
Interventions
BIOLOGICAL

Placebo

immunization schedule：Month 0，Month 2，Month 6

BIOLOGICAL

15-valent recombinant human papillomavirus vaccine (Hansenulapolymorpha)

immunization schedule：Month 0，Month 2，Month 6

Trial Locations (1)

Unknown

Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, Guangxi

All Listed Sponsors
lead

Shanghai Bovax Biotechnology Co., Ltd.

INDUSTRY

NCT06454175 - A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years | Biotech Hunter | Biotech Hunter